All News

#ACR21 TM26. Familial chilblains lupus seen in genetic mutation in Three Prime Repair Exonuclease 1 (TREX1). Suspected due to onset in infancy. @Rheumnow https://t.co/ZryOpeoJT8 https://t.co/LqZqoGDAL2

Links:

Eric Dein ericdeinmd ( View Tweet)
#ACR21 Late breaking #ACRambassador Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled EMR Data Repository https://t.co/oyovR27Upm

Links:

Marie Kuchynski MD Doctorkuch ( View Tweet)

#ACR21 [Dr Pooni] #Telemedicine #Pediatrics providers felt PE was worsened BUT msk exam was the MOST reliable. @endocrine_witch @millennialpedia https://t.co/3FGCyBIxB2 https://t.co/fgwdk0WXKm

Links:

LiSa ◡̈︎ rheumarhyme ( View Tweet)
👌Superb review of #SSc ILD by @sclerodermaUM #ACR21 👉EARLY/SUBCLINICAL is NOT Mild ILD 👉MMF 1st 👉TCZ in combination for progressive phenotype/progression 👉Nintedanib:start slow, uptitrate for GI tolerability 👉Early HSCT referral (early dcSSc, FVC&DLCO 45-80%, Normal🫀) https://t.co/MUOhc3PakH
Ashima Makol MD AshimaMakol ( View Tweet)
ACR/EULAR Classification Criteria for ANCA vasculitis, updated from prior Similar disclaimer; these are for use AFTER the diagnosis of small or medium vasculitis has been made Great international effort, kudos to all involved #ACR21 #ACRambassador https://t.co/a29TVvzVF7
Mike Putman EBRheum ( View Tweet)
@ACRheum This 👇👇👇idea from @nighat I moderated a panel of women leaders in a virtual world - one of the attendees is a trainee from a 3rd world country and had a hard time finding ways to get help/collaboration for research studies; she wanted to know what she could do #ACR21 https://t.co/4Jn8jYUXME
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21 new 2022 classification criteria by ACR/EULAR for AAV 💥GPA-Sensitivity-92%, Specificity-94% 💥MPA-Sensitivity-91%, Specificity-94% 💥EGPA-Sensitivity-85%, Specificity-99% 💥Score based https://t.co/61SOl4Tovg
EnvisionRheumat ERheumat ( View Tweet)
Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study: 🔰Vaccine being “rushed” or “experimental” 🔰Safety of vaccine in the patients’ rheumatologic diagnoses 🔰Side effects 🔰Concern for Allergic reaction Abst#1589 #ACR21 @RheumNow https://t.co/xm15KxdA56
swethaann23 swethaann23 ( View Tweet)
Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2 Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteria https://t.co/YPc5fx9wAR #ACR21 Abst1945 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Retrospective chart review of rheumatic irAE patients: Persistent rheumatic irAE activity 🔼received GC Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp
swethaann23 swethaann23 ( View Tweet)
Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions. 🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use. 🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs https://t.co/Id658ocDVf #ACR21 Abst1777 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Prof. Ami Shah: Patients with #scleroderma have an ⬆ risk of #cancer vs. general population 📌Data from 3 recent meta-analysis: Scleroderma pts have 1.4 to 1.8 fold increased risk of cancer @RheumNow #ACR21 https://t.co/4uQN6y3tIn
sheila RHEUMarampa ( View Tweet)
Dr. Ami Shah shares her approach to cancer screening in patients with #scleroderma👇 @RheumNow #ACR21 https://t.co/chmlGe4iyl
sheila RHEUMarampa ( View Tweet)
TIF1-y: most dominant target in #cancer assoc'd #dermatomyositis 🔷Associated with cancer in every racial group tested; no assoc'n w/ juvenile DM @RheumNow #ACR21 https://t.co/rPg1CQuNka
sheila RHEUMarampa ( View Tweet)
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting. https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21. https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS

Links:

Dr. John Cush RheumNow ( View Tweet)
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof) It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus? https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T

Links:

Dr. John Cush RheumNow ( View Tweet)
AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently ⭐️🔽 clinic workload and better disease activity stratification Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk
swethaann23 swethaann23 ( View Tweet)
Abst 1515 Williams & colleagues studied role of CD4+ and CD8+ PD-1+ T cells in patients with early RA - CD4+ and CD8+ T PD-1+ T cells were dominant cell types in synovial tissue - 6 months after treatment, gene expression of CD4+ PD-1+ T cells decreased #ACR21 @RheumNow https://t.co/TWLym8oHuK
Akhil Sood MD AkhilSoodMD ( View Tweet)
⭐️From 2012 – 2017 NIS data significant 🔽 in sepsis, SSTI, and UTI in patients with PsA despite the increased use of biologics over the years ⭐️No statistical difference pneumonia trend in PsA Abst# 1783 #ACR21 @Rheumnow https://t.co/ToxgRb0acP
swethaann23 swethaann23 ( View Tweet)
×